HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Composite end point analyses of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation.

AbstractOBJECTIVE:
Non-vitamin K antagonist oral anticoagulants (NOACs) have been proposed as alternatives to vitamin K antagonists (VKAs). The aim of this study is to examine the efficacy and safety of NOACs compared with warfarin with composite end points in patients with atrial fibrillation.
METHODS:
This semi-systematic review performed a study of Phase III randomized controlled trials comparing NOACs with vitamin K antagonists (VKAs) in patient with atrial fibrillation using composite end points (combination of various clinical events). The use of composite end points allowed for combining efficacy and safety outcomes, thereby comparing the differences between NOAC and warfarin therapy from a clinical perspective.
RESULTS:
Treatment with NOAC compared with warfarin was associated with a significant reduction in the sum of stroke or non-CNS, systemic embolism and major bleeding (odds ratio 0.87; 95% CI: 0.82-0.91).
CONCLUSION:
Generally, NOACs were associated with a more favorable efficacy and safety profile compared with warfarin with regard to composite end points.
AuthorsAida Madzak, Torben Bjerregaard Larsen, Deirdre A Lane, Gregory Y H Lip, Peter Brønnum Nielsen
JournalExpert review of cardiovascular therapy (Expert Rev Cardiovasc Ther) Vol. 13 Issue 10 Pg. 1155-63 (Oct 2015) ISSN: 1744-8344 [Electronic] England
PMID26401923 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, Review, Systematic Review)
Chemical References
  • Anticoagulants
  • Fibrinolytic Agents
  • Vitamin K
  • Warfarin
Topics
  • Administration, Oral
  • Anticoagulants (therapeutic use)
  • Atrial Fibrillation (complications, drug therapy)
  • Embolism (prevention & control)
  • Fibrinolytic Agents (therapeutic use)
  • Hemorrhage (epidemiology)
  • Humans
  • Randomized Controlled Trials as Topic
  • Stroke (prevention & control)
  • Vitamin K (antagonists & inhibitors)
  • Warfarin (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: